Literature DB >> 27057442

A century of oncolysis evolves into oncolytic immunotherapy.

O Hemminki1, A Hemminki2.   

Abstract

Treating cancer patients with oncolytic viruses that activate the immune system to fight cancer is an increasingly appealing option. Potency of the approach seems promising while safety has been consistent. Biological correlative data indicates that combining oncolytic immunostimulatory viruses with other existing treatments is tempting and many trials are ongoing.

Entities:  

Year:  2015        PMID： 27057442      PMCID： PMC4801451          DOI： 10.1080/2162402X.2015.1074377

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

1.  Oncolytic adenovirus ICOVIR-7 in patients with advanced and refractory solid tumors.

Authors:  Petri Nokisalmi; Sari Pesonen; Sophie Escutenaire; Merja Särkioja; Mari Raki; Vincenzo Cerullo; Leena Laasonen; Ramon Alemany; Juan Rojas; Manel Cascallo; Kilian Guse; Maria Rajecki; Lotta Kangasniemi; Elina Haavisto; Aila Karioja-Kallio; Päivi Hannuksela; Minna Oksanen; Anna Kanerva; Timo Joensuu; Laura Ahtiainen; Akseli Hemminki
Journal:  Clin Cancer Res       Date:  2010-05-25       Impact factor: 12.531

2.  Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer.

Authors:  Otto Hemminki; Iulia Diaconu; Vincenzo Cerullo; Saila K Pesonen; Anna Kanerva; Timo Joensuu; Kalevi Kairemo; Leena Laasonen; Kaarina Partanen; Lotta Kangasniemi; Andre Lieber; Sari Pesonen; Akseli Hemminki
Journal:  Mol Ther       Date:  2012-08-07       Impact factor: 11.454

3.  Case-control estimation of the impact of oncolytic adenovirus on the survival of patients with refractory solid tumors.

Authors:  Anna Kanerva; Anniina Koski; Ilkka Liikanen; Minna Oksanen; Timo Joensuu; Otto Hemminki; Juni Palmgren; Kari Hemminki; Akseli Hemminki
Journal:  Mol Ther       Date:  2014-11-10       Impact factor: 11.454

4.  Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.

Authors:  Robert H I Andtbacka; Howard L Kaufman; Frances Collichio; Thomas Amatruda; Neil Senzer; Jason Chesney; Keith A Delman; Lynn E Spitler; Igor Puzanov; Sanjiv S Agarwala; Mohammed Milhem; Lee Cranmer; Brendan Curti; Karl Lewis; Merrick Ross; Troy Guthrie; Gerald P Linette; Gregory A Daniels; Kevin Harrington; Mark R Middleton; Wilson H Miller; Jonathan S Zager; Yining Ye; Bin Yao; Ai Li; Susan Doleman; Ari VanderWalde; Jennifer Gansert; Robert S Coffin
Journal:  J Clin Oncol       Date:  2015-05-26       Impact factor: 44.544

5.  [(18)F]-fluorodeoxyglucose positron emission tomography and computed tomography in response evaluation of oncolytic adenovirus treatments of patients with advanced cancer.

Authors:  Anniina Koski; Helena Ahtinen; Heidi Liljenback; Anne Roivainen; Anu Koskela; Minna Oksanen; Kaarina Partanen; Leena Laasonen; Kalevi Kairemo; Timo Joensuu; Akseli Hemminki
Journal:  Hum Gene Ther       Date:  2013-11-07       Impact factor: 5.695

6.  Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus.

Authors:  Anna Kanerva; Petri Nokisalmi; Iulia Diaconu; Anniina Koski; Vincenzo Cerullo; Ilkka Liikanen; Siri Tähtinen; Minna Oksanen; Raita Heiskanen; Saila Pesonen; Timo Joensuu; Tuomo Alanko; Kaarina Partanen; Leena Laasonen; Kalevi Kairemo; Sari Pesonen; Lotta Kangasniemi; Akseli Hemminki
Journal:  Clin Cancer Res       Date:  2013-03-14       Impact factor: 12.531

7.  In vivo magnetic resonance imaging and spectroscopy identifies oncolytic adenovirus responders.

Authors:  O Hemminki; R Immonen; J Närväinen; A Kipar; J Paasonen; K T Jokivarsi; H Yli-Ollila; P Soininen; K Partanen; T Joensuu; S Parvianen; S K Pesonen; A Koski; M Vähä-Koskela; V Cerullo; S Pesonen; O H Gröhn; A Hemminki
Journal:  Int J Cancer       Date:  2013-12-06       Impact factor: 7.396

8.  Immunological data from cancer patients treated with Ad5/3-E2F-Δ24-GMCSF suggests utility for tumor immunotherapy.

Authors:  Otto Hemminki; Suvi Parviainen; Juuso Juhila; Riku Turkki; Nina Linder; Johan Lundin; Matti Kankainen; Ari Ristimäki; Anniina Koski; Ilkka Liikanen; Minna Oksanen; Dirk M Nettelbeck; Kalevi Kairemo; Kaarina Partanen; Timo Joensuu; Anna Kanerva; Akseli Hemminki
Journal:  Oncotarget       Date:  2015-02-28

9.  Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy.

Authors:  Ilkka Liikanen; Anniina Koski; Maiju Merisalo-Soikkeli; Otto Hemminki; Minna Oksanen; Kalevi Kairemo; Timo Joensuu; Anna Kanerva; Akseli Hemminki
Journal:  Oncoimmunology       Date:  2015-04-02       Impact factor: 8.110

10.  Penton-dodecahedral particles trigger opening of intercellular junctions and facilitate viral spread during adenovirus serotype 3 infection of epithelial cells.

Authors:  Zhuo-Zhuang Lu; Hongjie Wang; Yiyi Zhang; Hua Cao; Zongyi Li; Pascal Fender; André Lieber
Journal:  PLoS Pathog       Date:  2013-10-31       Impact factor: 6.823
  10 in total
  7 in total

Review 1.  Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics.

Authors:  Abhishek D Garg; Sanket More; Nicole Rufo; Odeta Mece; Maria Livia Sassano; Patrizia Agostinis; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-10-04       Impact factor: 8.110

Review 2.  Targeting Autophagy for Oncolytic Immunotherapy.

Authors:  Lulu Hu; Ke Jiang; Chan Ding; Songshu Meng
Journal:  Biomedicines       Date:  2017-01-11

Review 3.  Oncolytic viruses for cancer immunotherapy.

Authors:  Otto Hemminki; João Manuel Dos Santos; Akseli Hemminki
Journal:  J Hematol Oncol       Date:  2020-06-29       Impact factor: 17.388

4.  Oncograms Visualize Factors Influencing Long-Term Survival of Cancer Patients Treated with Adenoviral Oncolytic Immunotherapy.

Authors:  Otto Hemminki; Minna Oksanen; Kristian Taipale; Ilkka Liikanen; Anniina Koski; Timo Joensuu; Anna Kanerva; Akseli Hemminki
Journal:  Mol Ther Oncolytics       Date:  2018-04-22       Impact factor: 7.200

5.  Comparison of Clinically Relevant Oncolytic Virus Platforms for Enhancing T Cell Therapy of Solid Tumors.

Authors:  Victor Cervera-Carrascon; Dafne C A Quixabeira; Riikka Havunen; Joao M Santos; Emma Kutvonen; James H A Clubb; Mikko Siurala; Camilla Heiniö; Sadia Zafar; Teija Koivula; Dave Lumen; Marjo Vaha; Arturo Garcia-Horsman; Anu J Airaksinen; Suvi Sorsa; Marjukka Anttila; Veijo Hukkanen; Anna Kanerva; Akseli Hemminki
Journal:  Mol Ther Oncolytics       Date:  2020-03-19       Impact factor: 7.200

Review 6.  Overview of the pre-clinical and clinical studies about the use of CAR-T cell therapy of cancer combined with oncolytic viruses.

Authors:  Ali Zarezadeh Mehrabadi; Fatemeh Roozbahani; Reza Ranjbar; Mahdieh Farzanehpour; Alireza Shahriary; Ruhollah Dorostkar; Hadi Esmaeili Gouvarchin Ghaleh
Journal:  World J Surg Oncol       Date:  2022-01-13       Impact factor: 2.754

7.  Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibition.

Authors:  Victor Cervera-Carrascon; Dafne C A Quixabeira; Joao Manuel Santos; Riikka Havunen; Sadia Zafar; Otto Hemminki; Camilla Heiniö; Eleonora Munaro; Mikko Siurala; Suvi Sorsa; Tuomas Mirtti; Petrus Järvinen; Markus Mildh; Harry Nisen; Antti Rannikko; Marjukka Anttila; Anna Kanerva; Akseli Hemminki
Journal:  Oncoimmunology       Date:  2020-05-22       Impact factor: 8.110
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.